StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Manas Jaiswal

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byManas JaiswalHorizon: NA (inferred Swing (≤2wk))7 Sept 2026via CNBC Awaaz.

Entry₹1,161.7Inferred
Target₹1,200
Total upside +3.30% (call closed)
Stop loss₹1,124-3.25% risk
Exit₹1,12410 Sept 2026, 9:30 am
Stop-loss hit-3.25%
Follow Manas Jaiswal for new calls(30% target hit, 379 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 10 Sept 2026
4 supporting1 neutral0 opposing
Supports the BUY call (4)

India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth

NewsNdtv-Profit·9 Sept · today

(opens in new tab)

Zydus Lifesciences announced positive topline results from the completed EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg for MASH.

BSE · Company Update·31 Aug · 1w ago

(opens in new tab)

Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why

NewsNdtv-Profit·27 Aug · 2w ago

(opens in new tab)

1 advisor has an active short-term BUY call on this stock

Advisor consensus · adjacent horizon·12 Aug · 4w ago

Neutral / worth noting (1)

Zydus Pharmaceuticals USA Inc., a subsidiary of Zydus Lifesciences, has agreed to pay USD 5.9 million to settle litigation in the US District Court for the Eastern District of Pennsylvania. The settle

BSE · Company Update·5 Sept · 4d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Manas Jaiswal

Every call and its outcome